← Oncology Approval Tracker

FDA DECISION ·

Tregzi

allogeneic regulatory T-cell immunotherapy with HSPC and T cells-vldq · Orca Bio

FDA approvalNew therapyHematologic malignancies
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with hematologic malignancies undergoing matched-donor hematopoietic stem-cell transplantation with myeloablative conditioning. The use supports blood and immune-cell reconstitution and improves chronic graft-versus-host disease-free survival.

LAMPGEN ANALYSIS

Why it matters

This adds a donor-derived graft strategy for adults undergoing transplant. Precision-T assessed chronic graft-versus-host disease-free survival against an unmanipulated allograft.

What research teams should watch

Coordinate donor matching, chain of identity, manufacturing and transplant timing. Follow graft-versus-host disease assessments and prolonged post-transplant monitoring across the care team.

PRIMARY RECORDS

Sources